Gatipotuzumab Biosimilar – Anti-MUC1, CD227 mAb – Research Grade

About Gatipotuzumab biosimilar

Gatipotuzumab is a humanized monoclonal antibody, wih a specific glycosylation. It is able to recognize a tumor-specific epitope expressed on the surface of epithelial tumor cells. This target is an abnormal glycosylation on mucin-1, a glycosylated protein protecting epithelial surfaces. This tumor specific epitope is called TA-MUC1 and is overexpressed in epithelial cancer. Gatipotuzumab should have then an anti-tumor activity which has been already proved in a first clinical trial of phase I.Gatipotuzumab is able to distinguish between tumor MUC1 and non-tumor MUC1 epitopes. Its bond to the TA-MUC1 epitope induces Antibody-dependent cell-mediated cytotoxicity (ADCC) against epithelial tumor cells expressing this epitope. ADCC is a defense mechanism of the immune system.

About anti MUC1 activity

Gatipotuzumab is developed with a specific glycosylation process which is altering the glycosylation in the Fc region of the monoclonal antibody molecule. This development enhances immunogenicity and causes a stronger ADCC response.

About Mucins

Mucins are O-glycosylated proteins playing an overriding role in the protection of epithelial surfaces, by creating mucous barriers. These proteins also are intracellular signaling factors, and are expressed on the apical surface of epithelial cells that are found on the mucosal surfaces. Mucins are cleaved into two subunits (alpha and beta) by proteolysis: these subunits form a heterodimer. The N-terminal alpha subunit is involved in cell-adhesion; the C-terminal beta subunit is meanwhile involved in cell signaling.